Are Prescription Probiotics on the Horizon?
Last April, the Food and Drug Administration approved Seres Therapeutics’ Vowst, the nation’s first microbiome-based prescription product. In so doing, the agency quietly opened up an entirely new, potentially vast product category. Indicated for the prevention of recurrent Clostridioides difficile (aka “C diff”) infection in adults, Vowst contains live microbial spores derived from healthy human […]